Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non-small cell lung cancer from proteomic profiling of circulating extracellular vesicles.

In the multivariate logistic regression analysis evaluating the risk factors for symptomatic pneumonitis, EV‐RELA was identified as a significant risk factor (RELA: p = 0.008, OR 7.72 [95% CI: 1.70–35.0]), whereas V20 and PD‐L1 expression exhibited a trend towards increased risk; however, they did not reach statistical significance (Table S4 ).

also in 111,027 other papers